Besides GLUT1 as a target, targeting MM cells with ritonavir (GLUT4 inhibitor) increases the cytotoxic sensitivity and, together with the BH3 mimetic venetoclax, synergistic effects occur [97,98]. Here, SLC2A4 is linked to Miyoshi myopathy.